Merck: successful appeal against Viatris
(CercleFinance.com) - Merck today announced that the US Court of Appeals for the Federal Circuit has ruled in favor of Merck in a patent challenge filed by Mylan Pharmaceuticals (now Viatris) regarding sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA (sitagliptin), JANUMET (sitagliptin and metformin hydrochloride), and JANUMET XR (sitagliptin and metformin hydrochloride extended-release).
Viatris had challenged the validity before the Patent Office. However, on 7 May 2021, the Patent Office ruled in Merck's favor, declaring all contested claims valid. Viatris appealed this decision to the Federal Circuit Court of Appeals, which today affirmed the lower court's decision.
Today's decision by the Court of Appeals grants patent protection to JANUVIA, JANUMET and JANUMET XR until May 2027.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Viatris had challenged the validity before the Patent Office. However, on 7 May 2021, the Patent Office ruled in Merck's favor, declaring all contested claims valid. Viatris appealed this decision to the Federal Circuit Court of Appeals, which today affirmed the lower court's decision.
Today's decision by the Court of Appeals grants patent protection to JANUVIA, JANUMET and JANUMET XR until May 2027.
Copyright (c) 2022 CercleFinance.com. All rights reserved.